New Real-World MAVENCLAD® Data Show Sustained Effectiveness and Benefit on Quality-of-Life Measures in RMS Patients
Merck today announced new interim real-world data on MAVENCLAD® (cladribine tablets) that show patients with relapsing multiple sclerosis (RMS) experienced a significant improvement in quality-of-life (QoL) scores after the first course of treatment in Year 1 with MAVENCLAD. Additionally, late-breaking real-world MAVENCLAD data evaluating long-term mobility and disability status suggested sustained benefit beyond the last treatment course and a reduced need for a wheelchair or ambulatory device among MAVENCLAD-treated patients. These data were presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
New Data Presented at ECTRIMS Show Evobrutinib is First BTK Inhibitor to Demonstrate a Significant Reduction in Slowly Expanding Lesions (SEL) in Patients with RMS
Merck, a leading science and technology company, today shared data in an oral presentation from a Phase II post-hoc analysis, demonstrating that the o...
19/10/2021PRESS RELEASE Research Findings
Merck today announced enrolment has been completed in the Phase III EVOLUTION RMS clinical trial programme, which is evaluating the efficacy and safet...
12/10/2021PRESS RELEASE Corporate Announcements